SHREECEM vs ULTRACEMCO
Side-by-side comparison of Shree Cement Ltd. and UltraTech Cement Ltd.. Descriptive only — not investment advice.
Shree Cement Ltd.
Cement
Quality Score: 60/100
UltraTech Cement Ltd.
Cement
Quality Score: 61/100
At a glance
| Metric | SHREECEM | ULTRACEMCO |
|---|---|---|
| Quality Score | 60/100 | 61/100 |
| P/E (trailing) | 56.5 | 41.7 |
| Forward P/E | 37.0 | 28.0 |
| ROE | — | — |
| Profit margin | +14.5% | +9.3% |
| Debt-to-equity | 38.15 | 29.43 |
| Dividend yield | +0.54% | +1.98% |
| 1Y price return | -14.2% | +0.4% |
| From 52w high | -17.8% | -5.8% |
| Analyst rating1 = Strong Buy, 5 = Strong Sell | 2.38 | 1.45 |
Highlighted value = better on the metric (lower for P/E, D/E, drawdown, analyst rating; higher elsewhere). Descriptive only.
Snapshots
Shree Cement trades at Rs 26,100, up 4.57% over the past 3 months but still down 14.16% over the trailing 12 months and 17.79% below its 52-week high. The stock sits above both its 50-DMA (Rs 25,775.36) and 200-DMA (Rs 25,835.57) with a neutral RSI of 46.51. Trailing PE of 56.50 (forward 37.00) is the highest among the 6-stock cement peer set tracked, against 5-year revenue growth of 5.2% and 5-year earnings growth of 3.4%.
ULTRACEMCO trades at ₹12,105, up 0.44% over the past 12 months and 6.73% over the past 3 months, sitting 5.78% below its 52-week high and above both its 50-day and 200-day moving averages. Trailing PE of 41.67x ranks 4th of 6 in the cement sector while forward PE of 28.01x is lower, alongside 5-year revenue growth of 15.9% and earnings growth of 16.8%. Analyst consensus across 38 analysts stands at 1.45 on a 1-5 scale (lower = more constructive).
Pros
- ✓Quality score of 39 ranks 2nd of 6 among tracked cement peers (GRASIM 25, ULTRACEMCO 43, AMBUJACEM 19, ACC 21, DALBHARAT 30).
- ✓Debt-to-equity trend is described as falling in persistence data, with a debt-to-equity ratio of roughly 0.38x.
- ✓Recent news flow includes a reported 10% revenue beat versus analyst estimates (simplywall.st, 2026-08-04) and an approved final dividend for FY26 (marketscreener.com, 2026-08-01).
- ✓Price trades above both the 50-DMA and 200-DMA with a neutral RSI of 46.51, and is up 4.57% over the past 3 months.
- ✓Quality score of 43 ranks 1st of 6 among tracked cement peers (Grasim 25, Shree Cement 39, Dalmia Bharat 30, ACC 21, Ambuja Cements 19).
- ✓Free cash flow was positive in 4 of the last 5 years tracked, with debt-to-equity at a low approximately 0.29x.
- ✓5-year revenue growth of 15.9% and earnings growth of 16.8%, alongside a forward PE of 28.01x below the trailing 41.67x.
- ✓Analyst consensus of 1.45 across 38 analysts (1-5 scale, lower = more constructive), among the more constructive readings in the dataset.
Cons
- ✗Trailing PE of 56.50 is the highest among the 6-stock cement peer set tracked, ranking last (6 of 6) on the PE metric, against 5-year revenue growth of 5.2% and earnings growth of 3.4%.
- ✗Persistence data shows 0 years with ROE above 15% and a consistency score of 41/100; current-period ROE is not available.
- ✗Stock remains 17.79% below its 52-week high and down 14.16% over the trailing 12 months, despite trading above both moving averages.
- ✗1-year price-change data is null for all 5 tracked cement peers and current ROE is null for 4 of 5 peers, limiting direct sector-relative comparison on momentum and returns.
- ✗Return on equity has not exceeded 15% in any of the years tracked (roeYearsAbove15 = 0), despite the top quality-score ranking among peers.
- ✗Debt-to-equity trend is recorded as rising, even though the absolute level (approximately 0.29x) remains low.
- ✗12-month price change is close to flat at +0.44%, despite the stock trading above both moving averages and near its 52-week high.
- ✗Sector-peer comparison is data-limited: 12-month price change is unavailable for all five peers and ROE for four of five, and no resistance levels were identified for the stock itself.
Want the full analysis for either stock?
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Comparison reflects current public data; consult a registered adviser before any investment decision.